<DOC>
	<DOCNO>NCT02623504</DOCNO>
	<brief_summary>A phase 4 unequal randomization , double blind study evaluate dose tolerance safety extend release Equetro ( carbamazepine ) versus placebo follow Open label long term maintenance treatment child adolescent age 10-17 year diagnose acute manic mixed Bipolar I Disorder</brief_summary>
	<brief_title>DB/Maintenance Equetro ( Carbamazepine ) Children With Acute Manic Mixed Bipolar 1 Disorder</brief_title>
	<detailed_description>The primary objective study evaluate double blind condition dose tolerance safety extend release Equetro ( carbamazepine ) versus placebo follow open label long term maintenance treatment extend release Equetro child adolescent age 10-17 year diagnose acute manic mixed bipolar I disorder . The safety evaluation base occurrence treatment-emergent adverse event , laboratory value , physical examination , vital sign ECG trough serum level study medication . The secondary objective evaluate double blind condition efficacy extend release Equetro versus placebo follow open label long term maintenance treatment extend release Equetro child Adolescents Aged 10-17 year diagnose acute manic mixed Bipolar I disorder . Efficacy evaluation base measure YMRS , CGI-S , CGI-I , CDRS-R. Manic episodes double blind open label period comprise use study medication duration night time sleep monitor use daily diary . Subject 's enrolled double blind period two month evaluate weekly basis . Once complete db phase continue Equetro long term maintenance additional six month . Placebo subject opportunity continue another eight month study . The first two month titration period do db phase option continue study open long term maintenance additional 6 month . During maintenance period subject evaluate safety efficacy monthly basis . At end study 30 day follow-up .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Written , sign date informed consent subject , parent legal guardian . Subject must willing participate duration study ( 810 month ) Subject must meet DSMV criterion primary diagnosis bipolar I disorder . MINI KID administer ruled psychiatric diagnosis . ADHD Rating ScaleIV rule negative . YMRS Score 20 great CGIS score 4 great CGII Global Evaluation score 4 less Must age 10 17 year Male nonpregnant , nonlactating female agree comply contraceptive requirement Functioning age appropriate level intellectually deem Investigator Subject comorbid condition would affect efficacy , safety tolerability way interfere subject 's participation study Subject , parent legal guardian able willing comply study procedure restriction Must satisfactory medical assessment clinically significant abnormality Able avoid grapefruit grapefruit juice duration study Subject current control uncontrolled comorbid psychiatric could interfere clinical assessment study conduct . Naive subject whose symptom control prescribed medication ( ) eligible participate . History lack therapeutic response adequate trial carbamazepine treat bipolar I disorder Believed Investigator acutely risk suicidal violent behavior towards him/her others , history suicide attempt require general medical intervention Subject 's bipolar diagnosis believe secondary traumatic injury another general medical condition . A history know presence clinically significant cardiovascular , hepatic , hematological , immunological ( include human immunodeficiency virus , gastrointestinal renal disease unstable medical illness could affect action , absorption disposition investigational product , clinical laboratory assessment A history aplastic anemia , agranulocytosis bone marrow depression A history seizure disorder , single childhood febrile seizure\ A history severe , unstable asthma Currently hospitalize treatment psychiatric symptom . Presence mental disorder due general medical condition Presence abnormal thyroid function adequately treated opinion Investigator Use ECT , investigational drug , CYP450 3A4 inhibitor , antidepressant , anxiolytic , sedative hypnotic , antipsychotic , mood stabilizer , ADHD medication , clozapine specified time period prior initiation study Use nutraceutical include , limited counter herbal preparation e.g . Gingko Biloba , St John 's Wort , Kava Kava Ephedra . Positive urine drug screen History alcohol substance abuse dependence define DSMV ( except caffeine nicotine ) within last 6months Female subject positive pregnancy test pregnant , lactate , less 6 month post partum , rely upon use adequate birth control Subjects previously enrol Phase IV MultiCenter , OpenLabel Safety Effectiveness Study ExtendedRelease Carbamazepine Treatment Acute Manic Mixed Bipolar I Disorder subsequently withdraw Subjects body weight â‰¤65kg Family investigational site staff</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Carbamazepine</keyword>
	<keyword>Equetro</keyword>
	<keyword>Bipolar I Disorder</keyword>
	<keyword>Bipolar I Disorder Children</keyword>
</DOC>